

Volume 363, Number 9421 • Founded 1823 • Published weekly • Saturday May 15, 2004

EDITORIAL

1565 **Political neglect in India's health**

COMMENTARY

1566 **Dangerous pathogens in the laboratory: from smallpox to today's SARS setbacks and tomorrow's polio-free world**

D L Heymann and others

1568 **How to prevent cannabis-induced psychological distress . . . in politicians**

F Grotenhermen

1569 **Psychological, physiological, and drug interventions for type 2 diabetes**

D J A Jenkins

1570 **Statins for the treatment of multiple sclerosis: cautious hope**

C H Polman, J Killestein

ARTICLES

1571 **Breastmilk feeding and lipoprotein profile in adolescents born preterm**

A Singhal and others

1579 **Psychological and social sequelae of cannabis and other illicit drug use by young people**

J Macleod and others

1589 **Systematic review and meta-analysis of randomised controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes**

K Ismail and others

1598 **Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults**

K I Barnes and others

CASE REPORT

1606 **Progressive binasal hemianopia**

E Pringle and others

RESEARCH LETTERS

1607 **Oral simvastatin treatment in relapsing-remitting multiple sclerosis**

T Vollmer and others

1608 **Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites**

A Albillos and others

NEWS

1611 **US criticises Bulgarian nurses' conviction**

1612 **Central American trade pact may limit access to generics**

1614 **World Trade Center rescuers face lung distress**

NIH panel calls for limits on consulting

1615 **WHO puts HIV/AIDS pandemic at top of its agenda**

Canada draws near to approving Africa drugs deal

1616 **Pregnancy complications kill 70 000 teenagers a year**

Spanish HIV registry should be abolished, court rules

1617 **News in brief**

1618 **Bush accused of financially neglecting research**

SEMINAR

1619 **Cerebral palsy**

L A Koman and others

PERSONAL ACCOUNT

1632 **Yes, survive I did . . .**

J Geppert

REVIEW

1633 **Preimplantation genetic diagnosis**

K Sermon and others

VIEWPOINT

1642 **Early origins of cardiovascular disease: is there a unifying hypothesis?**

A Singhal, A Lucas

Contents list continues inside



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

040572 LANCET - INCLUDING INDEX
2004 VOLUME 363 ISSUE 9421
SISAC
26446025
952911

Exhibit
Exhibit No.: 2054
Name: 1PR2018-1403
Date: 4-26-19

THE LANCET

Volume 363, Number 9421 • Founded 1823 • Published weekly • Saturday May 15, 2004

London Editorial Office

THE LANCET
32 Jamestown Road,
London NW1 7BY, UK
Tel +44 (0)20 7424 4910
Fax +44 (0)20 7424 4911

New York Editorial Office

THE LANCET
360 Park Avenue South,
New York, NY 10010-1710, USA
Tel +1 212 633 3810
Fax +1 212 633 3853

Website

www.thelancet.com

e-mail address

editorial@lancet.com

Editor

Richard Horton

Deputy editor

Astrid James

Executive editors

Sabine Kleinert

David McNamee

Pia Pini

Charles Young

Managing editor

Stephanie Clark

Senior editors

Hannah Brown

Helen Frankish

Laragh Golligly

Delphine Grynszpan

Zoë Mullan

Joanna Palmer

Sarah Ramsay

Stuart Spencer

William Summerskill

Sarah Venis

North American editor

Michael McCarthy (Seattle)

Tel +1 206 706 7461

North American

senior editor

Faith McLellan

(New York)

European senior editor

Patricia Schlagenhaut (Zurich)

Tel +41 1 362 7604

Senior assistant editors

Lucy Banham

Sarah Passey

Abigail Pound

Wendy Sharpe

Assistant editors

Vivien Chen

Edward Morrison

Priya Shetty

Laura Thomas

Editorial researcher

Rachael Davies

Editorial assistant

Vrinder Heer

Web content coordinator

Stephanie Bartlett

Contributing editors

Dorothy Bonn

Dan Greenberg

William Jeffcoate

Marilynn Larkin

Fiona Matthews

David Sharp

CORRESPONDENCE

1646 Post-traumatic stress in former Ugandan child soldiers

S McKay, M G Wessells;

I Derluyn and others;

C Magambo, R Lett;

K A L A Kuruppuarachchi, L T Wijeratne;

S Singh

1648 Unsafe injections and transmission of HIV-1 in sub-Saharan Africa

D Gisselquist and others;

G P Schmid and others;

M Bulterys and others;

M Thoma and others

1651 Rising dengue death toll in Indonesia

S C Arya, A Varma

1651 Patients' charges in Slovakia

P Celec

1651 European Clinical Trials Directive: the Italian position

U Filibeck and others

1652 A need to rethink social psychiatry in Europe

W Rutz

OBITUARY

1653 Wayne Streilein T Tannen

DISSECTING ROOM

1654 More than I wanted to know J Hill

1655 Lost in translation (and transcription and replication) F McLellan

1656 A tug of war between ethics and commercialisation R Calne

1656 Young people with dementia G Smith

1657 Evidence M Edwards

1658 Lifeline P Webb

1658 Meeting fatigue J A Lee

CLINICAL PICTURE

1578 Cystic bronchiectasis E Coche and others

Information for authors: Guidelines for authors are published in the first issue of every month, immediately after Dissecting Room, and every week on *The Lancet* website

INTERNATIONAL ADVISORY BOARD

Karen Antman (New York)

Valerie Berat (Oxford)

Robert Bevilacqua (Boston)

Johan Giesecke (Stockholm)

David Grimes (Durham)

Elizabeth Molyneux (Blantyre)

Alwyn Mwinga (Lusaka)

Frank Shann (Melbourne)

Anne Tattersfield (Nottingham)

**DOCKET
ALARM**

Find authenticated court documents without watermarks at docketalarm.com.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Ltd, and the following terms and conditions apply to their use. The Lancet® is a registered trademark.

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Permissions may be sought directly from Elsevier Ltd, Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: permissions@elsevier.co.uk. You may also contact Global Rights directly through Elsevier's homepage (<http://www.elsevier.nl>), by selecting "Obtaining permissions".

In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: +1 (978) 7508400, fax: +1 (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments.

Derivative works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution.

Permission of the Publisher is required for all other derivative works, including compilations and translations.

Electronic storage or usage

Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article.

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission of the Publisher.

Address permissions requests to: Elsevier Ltd, Global Rights Department, at the mail, fax, and e-mail addresses noted above.

Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. All copy is subject to approval by the editors. The Publisher will not be liable for any loss occasioned by failure of any advertisement to appear from any cause.

Cancellations

Refunds cannot normally be issued once subscription has commenced.

Change of address

Please notify any change of address at least 21 days in advance.

Missing issues

Claims for damaged or missing issues should be made within three months of the date of the issue.

Reprints

Reprints of articles are available in minimum quantities of 100. For a price quotation contact Sarah Downes-Wall in London or Domenick Marmorato in New York.

Online availability

The Lancet is available on the internet at: <http://www.thelancet.com>

Microform

The Lancet is available in microform from ProQuest Information and Learning. For more information call UK +44 (0) 1223 215512 USA +1 734 7614 700

London Office

THE LANCET
Elsevier Ltd,
32 Jamestown Road,
London NW1 7BY, UK
T) +44 (0)20 7424 4910
F) +44 (0)20 7424 4911

Publisher

Richard Horton
Circulation Manager
Margarita Turner
PR & Press Officer
Richard Lane

Production

Production Manager
Nicola Carter
Production Controller
Debbie Heather
Senior Production Editor
Andrew Bell

Production Editors

Elaine Duff
Seema Patel
Hendrik Wittkopf
Production Co-ordinator
Claire Smith

Illustrators

Stephen Wood
David Shand
Electronic Production Controller
Marcus Boyle
Quality Controller
Colin Lake

Sales and Marketing

Director of Marketing
Vincent Cassidy
Classified Sales Executive
Tom Holburn
Sales Co-ordinator
Helen Fogarty
International Reprints Manager
Sarah Downes
Reprints Administrator
Caroline Caulton
Advertising Executive
Fleur Wintle
International Marketing Manager
Donna Walton
Marketing Executive
Marcus Parker
Marketing Administrator
Stuart Rowe

Journal Office

Operations Manager
Mark Harrington
PA to Editor
Hopelyn Goodwin
PA to Deputy Editor
Rose Bryan
PA to Executive Editors
Rosalind Nichols
Senior Administrators
Desdemon Burndam
Devonia Colton
Administrator
Nani Clanscy
Assistant Administrators
Leighton Cooper
Cynthia Mrwebi
Payments Administrator
Rebecca Cotton

New York Office

THE LANCET
Elsevier Inc,
360 Park Avenue South,
New York, NY 10010-1710, USA
T) +1 212 633 3810
F) +1 212 633 3850
Reprints Manager
Domenick Marmorato
Classified Advertising Representative
Danny Wang
Display Advertising Representatives
Henry J Blaney
E) h.blaney@elsevier.com
Georgia Nikolarios
E) g.nikolarios@elsevier.com

Philadelphia Office

THE LANCET
Elsevier Inc,
170 S Independence Mall W 300 E,
Philadelphia, PA 19106-3399, USA
T) +1 215 238 7800
F) +1 215 238 6423
North American Marketing Manager
Gretchen Hauselt

Subscription Customer Service

Customer Service Manager Katy Budgen

Eur/ROW T) +44 (0)1865 843 077
F) +44 (0)1865 843 970
E) custserv@lancet.com
N America T Direct) +1 (407) 345 4033
T Toll Free) +1 (800) 462 6198
F Direct) +1 (407) 363 1354
F Toll Free) +1 (800) 327 9021
E) USLancetCS@elsevier.com

Annual subscription rates

	UK	Europe	North America	Japan	Rest of World
Institutional Rate	£499	€724	US\$676	¥103,000	US\$774
Personal Rate	£112	€162	US\$151	¥26,000	US\$196
Reduced Rate*	£66	€96	US\$82	¥14,000	US\$103
Student Rate*	£49	€71	US\$66	¥11,000	US\$80
Back Issue current volume	£5	€30	US\$30	¥5,000	US\$30
Back Issue previous volumes	£11	€30	US\$30	¥5,000	US\$30

For subscriptions in the following US states please add the applicable tax: CA, CO, DC, MA, NJ, NY. GST is payable on orders in Canada. (GST no. 138066816). Please add tax as applicable in the EU.

Subscription types

Institutional Applies to libraries, institutions and individuals whose employer pays for their subscription.
Personal Applies to individuals paying with a personal cheque or credit card. No company/institutional cheques accepted.
Reduced Applies to junior doctors within 5 years of qualification and postgraduate students in full or part-time study, paying with a personal cheque or credit card. No company/institutional cheques accepted.

On-line access Full-text access to the subscribed title is available after completion of a simple registration/subscription process online.

Geographic areas

United Kingdom (UK) Applies to England, Scotland, Wales and Northern Ireland only.
Europe (EU) Applies to all European Union countries (except UK), irrespective of single currency (Euro) adoption.
North America (NAM) Applies to the US, Canada, Puerto Rico and the US Virgin Islands.

Research letters

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

Timothy Vollmer, Lyndon Key, Valerie Durkalski, William Tyor, John Corbooy, Silva Markovic-Plese, Jana Preiningerova, Marco Rizzo, Inderjit Singh

Many drugs have been approved for relapsing forms of multiple sclerosis but are only partly effective, are injected, and are expensive. We aimed to investigate use of oral simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis. The mean number of gadolinium-enhancing lesions at months 4, 5, and 6 of treatment was compared with the mean number of lesions noted on pretreatment brain MRI scans. Number and volume of Gd-enhancing lesions declined by 44%, ($p < 0.0001$) and 41% ($p = 0.0018$), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability.

Lancet 2004; **363**: 1607–08
See Commentary page 1570

Since 1993, five disease-modifying drugs have been approved for relapsing forms of multiple sclerosis.¹ All these are only partly effective for most patients, need regular injections, and are expensive. Statins are cholesterol-lowering drugs extensively used in medical practice for primary and secondary prevention of cardiovascular events due to atherosclerosis. In addition to their cholesterol-lowering effect, previously unrecognised immunomodulatory effects have been identified.² Statins inhibit lymphocyte function associated antigen 1 (LFA-1)—a ligand for intercellular adhesion molecule (ICAM) that enables inflammatory cells to pass through the blood-brain barrier—and the production of matrix metalloproteinase 9, an enzyme associated with T-cell transmigration across endothelial barriers.³ Singh and his group (Pahan and colleagues,⁴ Stanislaus and colleagues⁵) reported the down-regulation of inflammatory mediators (such as tumour necrosis factor α and inducible nitric oxide synthase) in macrophages and glial cells in culture and experimental autoimmune

encephalomyelitis brain, a model for multiple sclerosis.⁴ Furthermore, Youssef and co-workers⁵ showed that statins induce a shift from production of proinflammatory (T-helper [Th] 1) cytokines to anti-inflammatory (Th2) cytokines in autoaggressive T cells. Thus, statins could be beneficial for multiple sclerosis. We aimed to assess use of oral simvastatin in patients with relapsing-remitting multiple sclerosis.

We designed a multi-centre, open-label, single-arm study to gather information on use of oral simvastatin. Between May, 2001, and February, 2002, we enrolled into a pre-treatment phase individuals who were aged 18–55 years with clinically definite relapsing-remitting multiple sclerosis and no previous treatment with interferons or glatiramer in the previous 3 months or corticosteroids within 30 days of screening. We monitored participants for 3 months, and did monthly brain MRI scans; those with at least one gadolinium-enhancing lesion detected during this phase were eligible to receive 80 mg of simvastatin daily for 6 months. We repeated brain MRI at months 4, 5, and 6 of treatment. All MRI scans were read by two expert masked readers who manually established the location of Gd-enhancing lesions. We measured the volume of lesions with a threshold technique. We identified the number of new Gd-enhancing lesions per scan by comparison of the location of lesions on consecutive scans during pretreatment and treatment phases, with masked order of phase.

The primary outcome measure was mean number of Gd-enhancing lesions on magnetisation transfer enhanced T1 images pretreatment and during treatment. Secondary MRI outcomes were volume of Gd-enhancing lesions, number of new Gd-enhancing lesions, and total T2 lesion volume plus a brain atrophy measure, which were quantified by one operator with semiautomated software (MSClassifier). Secondary clinical outcomes were relapse rate and change in expanded

	Baseline	Treatment	Average mean difference	p
Number of Gd-enhancing lesions*				
Mean (SD)	2.31 (1.39)	1.30 (0.99)	-1.01 (1.08)	<0.0001
Median	2	1	..	
Number of new Gd-enhancing lesions				
Mean (SD)	1.37 (1.53)	0.71 (0.68)	-0.679 (1.54)	0.0295
Median	1	0.50	..	
Volume of Gd-enhancing lesions (mm³)				
Mean (SD)	234 (262)	139 (235)	-98.3 (183.8)	0.0018
Median	172.5	71	..	
T2 lesion volume (mm³)				
Mean (SD)	27 019 (23 871)	27 994 (26 284)	862.5 (4605.5)	0.5634
Median	21 398	20 831	..	
Brain parenchymal fraction				
Mean (SD)	0.87 (0.041)	0.86 (0.040)	-0.002 (0.005)	0.0467
Median	0.88	0.88	..	
EDSS (mean)	2.80	2.98	..	0.6125
Yearly relapse rate (mean)	0.43	0.38	..	1.0

disability status score. We assessed adherence with monthly study drug records. We summarised all MRI outcome measures as the average of the mean values per participant and analysed them with the Wilcoxon signed rank test. We did exploratory immunology studies including serial measurement of cytokine production by in-vitro anti-CD3 plus anti-CD28 monoclonal antibody-stimulated peripheral blood mononuclear cells. We monitored secretion of Th1 (interferon γ , tumour necrosis factor α , interleukin 2, interleukin 12) and Th2 (interleukins 4, 6, and 10) cytokines. Further, we noted surface marker expression in a small cohort. Three-colour staining was done and we analysed results on lymphocyte-gated and monocyte-gated populations with Cell Quest software (version 3.3) (Beckton Dickinson Immunocytometry Systems, San Diego, CA, USA).

Of 45 people screened, 30 were eligible for treatment and two discontinued before completion of the three treatment MRI scans (one withdrew consent and one was lost to follow-up before the month 6 scan). Mean age was 44 years (SD 8), and 21 (70%) were women. Of the 28 per-protocol individuals, the average of the mean number of Gd-enhancing lesions was reduced by 44% during treatment compared with pretreatment ($p < 0.0001$; table). Similarly, Gd-enhancing lesion volume fell by 41% after treatment ($p = 0.0018$). Pretreatment and treatment phase yearly relapse rates did not differ. No relevant change between pretreatment and treatment expanded disability status scores was detected during the 6 month treatment period (table).

Mean baseline total cholesterol and LDL values were 5.0 mmol/L (SD 1.0) and 3.1 mmol/L (0.7) respectively. By treatment month 6, these amounts had fallen to 3.5 mmol/L (0.6) and 1.8 mmol/L (0.5), respectively ($p < 0.0001$). Treatment did not affect relative numbers of monocyte (CD14+) and lymphocyte (CD3+, CD4+, CD8+, CD19+) subsets in the cohort of nine patients. Overall, the findings of the immunology studies did not indicate a change in secretion of representative Th1 and Th2 cytokines. No serious adverse events were reported during the treatment phase. Two of the treated individuals had a clinically important increase in liver function tests during treatment and one had a clinically relevant creatinine phosphokinase concentration at month 1 of treatment that returned to normal for the rest of the treatment period. Three people reported muscle weakness possibly related to study drug.

These findings suggest that an 80 mg daily dose of oral simvastatin over a 6 month period could inhibit the inflammatory components of multiple sclerosis that lead to neurological disability. Since individuals were enrolled on the basis of their disease activity on baseline MRI scans, noted reductions in a baseline versus treatment trial design could represent regression to the mean. However, our results, combined with the published work on the immunological effects of statins, lend support to the case for randomised controlled clinical trials to establish the safety and efficacy of statins in the treatment of relapsing-remitting multiple sclerosis.

Contributors

L Key and I Singh were the study chairmen. V Durkalski was the study statistician and project leader at the Clinical Innovation Group (coordinating center). T Vollmer, S Markovic-Plese, W Tyor, and J Corboy were site investigators. J Preiningerova and M Rizzo worked at the central MRI reading center.

Conflict of interest statement

The Medical University of South Carolina and IS are participants in US patent no 6 511 800, an unlicensed patent about use of statins for treatment of neurodegenerative and inflammatory diseases. If the patent is licensed, financial distribution will be due according to the Medical University of South Carolina's intellectual property guidelines. IS is

Acknowledgments

This research was supported by an unrestricted educational grant from Merck to the Medical University of South Carolina. The sponsor had no role in study design, data collection, data analysis, data interpretation, or in the writing of the report.

- 1 Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. *Neurology* 2002; 58: 169-78.
- 2 Neuhavs O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: comparison with interferon-beta 1b in MS. *Neurology* 2002; 59: 990-97.
- 3 Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. *J Neurosci Res* 2001; 66: 155-62.
- 4 Pahan K, Sheikh F, Namboodiri A, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia and macrophages. *J Clin Invest* 1997; 100: 2671-79.
- 5 Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverse paralysis in central nervous system autoimmune disease. *Nature* 2002; 420: 78-84.

Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ, USA (T Vollmer MD); Medical University of South Carolina, Charleston, SC, USA (L Key MD, V Durkalski PhD, W Tyor MD, I Singh PhD); Clinical Innovation Group, Charleston, SC, USA (V Durkalski); Department of Neurology, University of North Carolina, Chapel Hill, NC, USA (S Markovic-Plese MD); Department of Neurology, Yale School of Medicine, New Haven, CT, USA (T Vollmer, S Markovic-Plese, J Preiningerova MD, M Rizzo MD); University of Colorado Health Sciences Center, Denver, CO, USA (J Corboy MD); Neurology Service, Ralph H Johnson Veterans Affairs Medical Center Charleston, SC, USA (W Tyor); Denver Veterans Affairs Medical Center, Denver, CO, USA (J Corboy); and West Haven Veterans Affairs Medical Center, West Haven, CT, USA (J Preiningerova)

Correspondence to: Dr Inderjit Singh, Medical University of South Carolina, 316 Clinical Science Building, 171 Ashley Avenue, Charleston, SC 29425, USA (e-mail: singhi@musc.edu)

Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites

Agustín Albillos, Antonio de-la-Hera, Melchor Alvarez-Mon

Serum lipopolysaccharide-binding protein is increased in a subset of non-infected ascitic cirrhotic patients, a finding previously related to bacterial passage from the gut to the circulation without overt infection. We prospectively analysed the risk factors associated with a first episode of severe bacterial infection in 84 ascitic cirrhotics, followed up for a median of 46 weeks. The cumulative probability of such infection in patients with raised and normal lipopolysaccharide-binding protein was 32.4% and 8.0% ($p = 0.004$), respectively. Increased lipopolysaccharide-binding protein was the only factor independently associated with severe bacterial infection in a multivariate analysis (relative risk 4.49, 95% CI 1.42-14.1). Monitoring of serum lipopolysaccharide-binding protein could, therefore, help to target cirrhotic patients with ascites for antibiotic prophylaxis.